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Mitochondrial respiration is important for cell prolif-
eration; however, the specific metabolic require-
ments fulfilled by respiration to support proliferation
have not been defined. Here, we show that a major
role of respiration in proliferating cells is to provide
electron acceptors for aspartate synthesis. This
finding is consistent with the observation that cells
lacking a functional respiratory chain are auxotrophic
for pyruvate, which serves as an exogenous electron
acceptor. Further, the pyruvate requirement can be
fulfilled with an alternative electron acceptor, alpha-
ketobutyrate, which provides cells neither carbon
nor ATP. Alpha-ketobutyrate restores proliferation
when respiration is inhibited, suggesting that an
alternative electron acceptor can substitute for respi-
ration to support proliferation. We find that electron
acceptors are limiting for producing aspartate, and
supplying aspartate enables proliferation of respira-
tion deficient cells in the absence of exogenous elec-
tron acceptors. Together, these data argue a major
function of respiration in proliferating cells is to sup-
port aspartate synthesis.
INTRODUCTION
In mammalian cells, mitochondrial respiration allows coupling of
nutrient oxidation toATPproduction. Respiration involves a series
of redox reactions where electrons from a reduced substrate are
ultimately transferred to molecular oxygen as the final electron
acceptor. This results in oxidation of consumed nutrients and
reduction of molecular oxygen to water. The free energy released
from this series of oxidation-reduction reactions is coupled topro-
duction of an electrochemical gradient that can be used to drive
ATP synthesis, membrane transport, and thermogenesis (Harms
and Seale, 2013; Mitchell, 1961; Schleyer et al., 1982).
While supporting bioenergetics is a critical function of respira-
tion inmammalian cells,manyproliferating cells display increased
fermentation, which alone can be sufficient to supply ATP (Got-552 Cell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc.tlieb and Tomlinson, 2005). In contrast to most normal tissues,
cancer cells consume increased amounts of glucose andmetab-
olizemuchof this glucose to lactate even in thepresenceof ample
oxygen (Koppenol et al., 2011; Warburg et al., 1924). This pheno-
type, termed aerobic glycolysis or theWarburg effect, was initially
hypothesized to result from diminished mitochondrial function
(Warburg, 1956). However, despite utilizing aerobic glycolysis,
most cancer cells also consume oxygen (Weinhouse, 1956; Zu
and Guppy, 2004). Notably, in cancer cell lines, the primary sub-
strate for oxidation is often not glucose but rather glutamine,
one of the most heavily consumed nutrients by cells in culture
(Fan et al., 2013; Kovacevic, 1971; Zielke et al., 1984). Thus, aer-
obic glycolysis likely does not replace mitochondrial respiration,
but rather, in proliferating cells these processes occur in parallel.
Most cells that engage in aerobic glycolysis are not only
capable of respiration, but also require respiration for prolifera-
tion. Exposure of cancer cells in culture to respiration inhibitors
blocks proliferation (Harris, 1980; Howell and Sager, 1979; Kroll
et al., 1983; Lo¨ffer and Schneider, 1982). In vivo, maintenance of
mtDNA is required for autochthonous tumor formation (Weinberg
et al., 2010), and inhibition of respiration suppresses tumor
growth in xenografts (Wheaton et al., 2014; Zhang et al., 2014).
These findings argue that mitochondrial respiration is essential
for rapid proliferation, but whether respiration is advantageous
for proliferation beyond producing ATP is less clear.
Despite the importance of respiration in mammalian cell prolif-
eration, under specific culture conditions proliferation is possible
even in the absence of respiration. Serial passage in low-dose
ethidium bromide produces cells devoid of mtDNA (r0 cells)
(King andAttardi, 1989, 1996). r0 cells lack a functionalmitochon-
drial electron transport chain (ETC), and these respiration-incom-
petent cells fail to proliferate unless supra-physiological levels
of uridine and pyruvate are present in the culture media (King
and Attardi, 1989). Uridine auxotrophy is explained by the fact
that the de novo pyrimidine biosynthesis enzyme dihydroorotate
dehydrogenase (DHODH) transfers electrons directly to the ETC
to convert dihydroorotate to orotate. Thus, loss of electron trans-
port toO2prevents this reaction, andexogenousuridine is needed
toproducepyrimidines (Gre´goire et al., 1984). The requirement for
pyruvate, however, was initially unexpected because cells defi-
cient in mtDNA are highly glycolytic and capable of generating
large amounts of pyruvate (King and Attardi, 1989).
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Figure 1. Cytochrome B Mutant 143B Cybrid Cells Are Auxotrophic
for Electron Acceptors that Can Regenerate NAD+
(A) Proliferation rate of 143B CytB cells was determined in the presence or
absence of pyruvate. (left) Cell counts, normalized to cell number at t = 0 when
media conditionswere applied, were assessed over time and used to calculate
proliferation rate (right).The fact that adding specific nutrients can substitute for respi-
ration suggests respiration fulfills specific metabolic require-
ments for proliferating cells. While ATP synthesis via oxidative
phosphorylation is often assumed to be the critical output of
respiration, neither exogenous uridine nor pyruvate can be
oxidized to supply ATP in the absence of respiration. However,
other than dihyroorotate to orotate conversion, the metabolic
function(s) that become limiting for proliferation in the absence
of respiration are unknown.
Here we show that loss of mitochondrial respiration causes
proliferating cells to become functionally limited for electron
acceptors. This lack of electron acceptors impairs de novo
aspartate synthesis and inhibits proliferation. Strikingly, this pro-
liferation block can be overcome by supplementing cells with
exogenous electron acceptors or by high levels of aspartate.
Taken together, our data argue that themost essential metabolic
function for proliferation provided by mitochondrial respiration is
to provide access to electron acceptors to support aspartate
biosynthesis.
RESULTS
Alpha-Ketobutyrate Can Substitute for Pyruvate to
Support Proliferation in Respiration-Incompetent Cells
Cells lacking a functional mitochondrial ETC require pyruvate for
proliferation (King and Attardi, 1989). This suggests that pyruvate
substitutes for an essential metabolic function of respiration. We
reasoned that better understanding the role of pyruvate in these
cells would allow us to gain insight into how respiration supports
the metabolic needs of proliferating cells. To avoid respiration-
independent effects of mtDNA depletion, we used 143B r0 cells
repopulated withmtDNA containing a frameshift deletion in cyto-
chrome B (143B CytB) (Rana et al., 2000). 143B CytB cells have
otherwise wild-type mitochondria, but are respiration-incompe-
tent due to lack of cytochrome B in complex III and thus lack
a functional ETC. As a control we utilized 143B r0 cells which
were repopulated with wild-type mtDNA (143B WT cybrid) and
are respiration-competent with a functional ETC. 143B CytB
cells are auxotrophic for pyruvate as they fail to proliferate in
the absence of pyruvate (Figure 1A). Conversely, 143B WT cy-
brid cells cultured with or without pyruvate divide at a similar
rate (Figure S1A), confirming that pyruvate auxotrophy accom-
panies loss of mitochondrial respiration.
Several hypotheses have been proposed to explain pyruvate
auxotrophy (Howell and Sager, 1979; King and Attardi, 1996;
Morais et al., 1994; van den Bogert et al., 1992). Pyruvate carbon(B) Pyruvate is a substrate of lactate dehydrogenase (LDH), accepting elec-
trons from NADH to produce NAD+ and lactate.
(C) Alpha-ketobutyrate (AKB) can also act as an electron acceptor from NADH
and yield NAD+ and alpha-hydroxybutyrate (AHB).
(D) Proliferation rate for 143B CytB cells in the presence or absence of AKB
was determined as in (A).
(E) Intracellular ratio of NAD+/NADH was determined in 143B CytB cells in
untreated media or in the presence of pyruvate (Pyr) or AKB.
(F) The concentration of AKB and AHB in themedia of 143B CytB cells cultured
in the presence of AKBwas determined over time by GCMS analysis. Values in
all figure panels denote mean ± SEM, n = 3.
See also Figure S1.
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has many metabolic fates, including conversion to oxaloacetate
via pyruvate carboxylase, malate via malic enzyme, and acetyl-
CoA via the pyruvate dehydrogenase complex. Thus, one hy-
pothesis is that pyruvate acts as a carbon substrate for synthesis
of biosynthetic intermediates that are normally dependent on
respiration. An alternative hypothesis is that in the absence of
functional ETC, cells cannot adequately oxidize cellular NADH.
Hence, pyruvate is required as an exogenous electron acceptor
to regenerate NAD+ via the lactate dehydrogenase (LDH)
reaction (Figure 1B). Importantly, the continued production of
pyruvate from glycolysis requires NAD+, and therefore, the use
of glucose-derived pyruvate as a biosynthetic intermediate re-
quires an exogenous source of NAD+ regeneration to maintain
redox balance.
In order to decouple the potential roles of pyruvate, we
sought alternative substrates that could support 143B CytB
cell proliferation in the absence of pyruvate. One candidate
we identified is the four-carbon metabolite alpha-ketobutyrate
(AKB), which can act as a substrate for LDH or other intracel-
lular dehydrogenases (Figure 1C). While not the preferred
substrate for LDH, we confirmed that LDH can utilize AKB to
regenerate NAD+ from NADH with reasonable kinetics (Fig-
ure S1B). We tested whether AKB is sufficient to support pro-
liferation of 143B CytB cells in the absence of pyruvate. Indeed,
AKB restores proliferation of 143B CytB cells to similar levels as
cells cultured with pyruvate (Figure 1D). AKB addition does not
restore oxygen consumption (Figure S1C), alleviate uridine
auxotrophy (Figure S1D), or impact proliferation of 143B WT
cybrids (Figure S1E), demonstrating that AKB acts similarly to
pyruvate in supporting proliferation of respiration-deficient
143B CytB cells.
As exogenous electron acceptors, AKB and pyruvate are both
expected to regenerate NAD+. We measured the NAD+/NADH
ratios in 143B CytB cells cultured in the absence or presence
of either pyruvate or AKB. Addition of either pyruvate or AKB
is sufficient to increase the NAD+/NADH ratio, consistent with
thesemolecules serving as electron acceptors (Figure 1E). Given
that AKB and pyruvate have different metabolic carbon-fates, we
hypothesized that AKB is used primarily as an electron acceptor
and not as a carbon substrate in other metabolic pathways.
When AKB is metabolized by a dehydrogenase that uses
NADH to reduce the alpha-ketone to a hydroxyl and regenerate
NAD+, the expected product is alpha-hydroxybutyrate (AHB)
(Figure 1C). To test whether this is the fate of exogenous AKB
in 143B CytB cells, we quantitatively measured the consumption
of AKB and excretion of AHB in the media of 143B CytB cells
cultured in the absence of pyruvate. We found that AKB con-
sumption matched AHB excretion (Figure 1F). AKB and AHB
are both four-carbon metabolites that differ only by oxidation
state, and levels of these metabolites in the culture media are
negligible when AKB is not added. Thus, this result strongly sug-
gests that AKB acts only as an electron acceptor and does not
directly contribute carbon to metabolism. To further confirm
that pyruvate and AKB carbon are metabolized differently, we
find that pyruvate, but not AKB, maintains viability of 143B WT
cybrid and HeLa cells deprived of glucose and glutamine
(Figure S1F). Since AKB is sufficient to replace pyruvate in sup-
porting 143B CytB cell proliferation, the pyruvate auxotrophy554 Cell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc.of these respiration incompetent cells is best explained as a
requirement for exogenous electron acceptors. Taken together,
these data suggest that access to exogenous electron acceptors
provided by respiration (O2), pyruvate, or AKB are required to
support proliferation.
Inhibition of Respiration Causes Auxotrophy for
Electron Acceptors
Generation of 143B CytB cells involves a selection process that
could result in uncharacterized changes that alter the metabolic
requirements provided by respiration. To test whether parental
cells with functional ETC have the same requirements for respi-
ration, we treated wild-type 143B cells with an array of respira-
tion inhibitors. Given the known DHODH requirement for respira-
tion and the finding that AKB can substitute for pyruvate as an
electron acceptor, this and all subsequent experiments were
performed in the presence of uridine and in the absence of pyru-
vate. Inhibitors of mitochondrial complex I, complex III, complex
IV, and ATP synthase were all sufficient to suppress proliferation
and most resulted in decreased cell count over time (Figure 2A).
Exposure to ETC inhibitors at these doses decreased oxygen
consumption (Figure S2) and thus decreased access to electron
acceptors. To determine if respiration is required for proliferation
because it provides access to electron acceptors, we tested if
AKB supplementation could restore proliferation. In all cases,
AKB addition rescued proliferation to rates comparable to that
of untreated cells (Figure 2A). To confirm that AKB also acts as
an electron acceptor in this context, we measured the NAD+/
NADH ratio in cells treated with ETC inhibitors in the absence
or presence of AKB. All ETC inhibitors decreased cellular
NAD+/NADH ratio in the absence of AKB (Figure 2B). AKB addi-
tion restored NAD+/NADH, while having no effect on O2 con-
sumption, confirming that AKB is sufficient to increase oxidized
cofactor pools (Figures 2B and S2).
To determine if a similar dependence on respiration exists in
other proliferating cells, we treated a panel of genetically diverse
cell lines including both transformed and non-transformed cells
with three representative respiration inhibitors: rotenone (com-
plex I inhibitor), antimycin (complex III inhibitor), and oligomycin
(ATP synthase inhibitor). For all cell lines, treatment with any of
the inhibitors blocked proliferation, and AKB was sufficient to
restore proliferation (Figure 2C).
The use of oxygen as a terminal electron acceptor by mito-
chondrial respiration is well described. However, this role for ox-
ygen is classically considered in the context of enabling NADH
oxidation by the ETC to produce a membrane potential across
the mitochondrial inner membrane and support ATP synthesis.
Notably, reduction of AKB allows regeneration of NAD+ but
does not support ATP production, arguing that mitochondrial
ATP production is not required for proliferation. To further test
this idea, we utilized oligomycin, a specific ATP synthase inhib-
itor, and the ionophore carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP), an uncoupler of the mitochondrial
membrane potential. In normal respiration, electrons from
NADH are transferred to the ETC and then ultimately to oxygen
to generate an electrochemical proton gradient across the mito-
chondrial inner membrane, which can drive ATP synthesis. Oli-
gomycin does not directly inhibit components of the ETC, but
Untr Rot Phen Ant Myxo N3 Oligo
0
2
4
6
N
A
D
+ 
/ N
A
D
H
143B - AKB
+ AKB
Untr Rot Phen Ant Myxo N3 Oligo
-0.8
-0.4
0.0
0.4
0.8
1.2
1.6
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
143B
Complex I Complex III Complex 
IV
ATP 
Synthase
Site of inhibition:
+ AKB
- AKB
A
C
B
Untr Rot Ant Oligo-0.2
0.0
0.2
0.4
0.6
0.8
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
A172
Untr Rot Ant Oligo-0.3
0.0
0.3
0.6
0.9
1.2
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
HeLa 
Untr Rot Ant Oligo-0.2
0.0
0.2
0.4
0.6
0.8
1.0
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
H1299
0.0
0.2
0.4
0.6
0.8
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
U87
-0.2
0.0
0.2
0.4
0.6
0.8
1.0
1.2
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
MEF
+ AKB
- AKB
-0.4
0.0
0.4
0.8
1.2
1.6
2.0
2.4
Pr
ol
ife
ra
tio
n 
R
at
e 
(d
ou
bl
in
gs
 / 
da
y)
FL5.12
Figure 2. Proliferation of Respiration-Inhibited Cells Is Restored by Exogenous Electron Acceptors
(A) The proliferation rate of 143B cells was determined in media with or without AKB supplementation in the absence (Untr) or in the presence of the mitochondrial
respiration inhibitors rotenone (Rot), phenformin (Phen), antimycin (Ant), myxothiazol (Myxo), azide (N3), or oligomycin (Oligo).
(B) The ratio of NAD+/NADH was determined in 143B cells with or without AKB supplementation in the absence or presence of respiration inhibitors as in (A).
(C) The proliferation rate of A172, H1299, HeLa, U87, FL5.12, andMEF cell lines was determined with or without AKB supplementation in the absence or presence
of rotenone, antimycin, or oligomycin. Values in all figure panels denote mean ± SEM, n = 3.
See also Figure S2.rather slows ETC electron transfer to oxygen by hyperpolarizing
the mitochondrial membrane potential (Figure 3A) (Brand and
Nicholls, 2011). Thus, treatment with oligomycin alone de-
creases oxygen consumption (Figure S2C). However, addition
of the uncoupling agent FCCP can restore the ability to transfer
electrons from the ETC to oxygen in the presence of oligomycin
by relieving membrane hyperpolarization without reversing inhi-
bition of ATP synthase function (Figure 3A). Thus, if providing ac-
cess to electron acceptors is the essential function of respiration
independent of ATP production, restoring oxygen consumption
with a low dose of FCCP that does not completely dissipate all
intracellular proton membrane potentials should restore prolifer-ation of oligomycin-treated cells. We compared the proliferation
rate of 143B cells cultured in oligomycin in the absence or
presence of low-dose FCCP. Consistent with the hypothesis,
FCCP addition increased proliferation of oligomycin-treated
cells (Figure 3B). Also in agreement with the hypothesis, FCCP
increased both oxygen consumption and the NAD+/NADH ratio
(Figures 3C and 3D). Since FCCP and oligomycin act indepen-
dently, FCCP addition does not restore mitochondrial ATP
production. These data argue that providing access to electron
acceptors, rather than supporting mitochondrial ATP produc-
tion, is a limiting function of mitochondrial respiration for sup-
porting proliferation.Cell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc. 555
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Figure 3. Oxygen Utilization in the Absence of Mitochondrial ATP Production is Sufficient for Cell Proliferation
(A) Schematic illustrating the effects of oligomycin and FCCP on mitochondrial membrane potential and ATP synthesis. Oligomycin treatment inhibits ATP
synthase, resulting in a hyperpolarized mitochondrial membrane. This hyperpolarization inhibits proton pumping and thereby inhibits ETC activity resulting in
decreased NADH oxidation and O2 consumption (left). Treatment with FCCP in addition to oligomycin relieves the hyperpolarization of the mitochondrial
membrane allowing restoration of NADH oxidation and mitochondrial O2 consumption without restoring ATP production (right).
(B) Proliferation rate of 143B cells treated with oligomycin in the presence or absence of FCCP treatment.
(C) Mitochondrial oxygen consumption rate of 143B cells treated with oligomycin with or without FCCP.
(D) Intracellular NAD+/NADH ratio in 143B cells treated with oligomycin in the presence or absence of FCCP.
Values in all figure panels denote mean ± SEM, n = 3 (B and D), n = 5 (C).Electron Acceptor Insufficiency Causes Inhibition of
Nucleotide Biosynthesis
To gain mechanistic insight into why electron acceptors are
required for proliferation, we characterized the phenotype of
respiration incompetent cells under conditions where access
to electron acceptors is limiting. Analysis of DNA content in
non-proliferating 143B CytB cells without AKB suggested that
these cells do not arrest at a specific stage of the cell cycle (Fig-
ure 4A). Surprisingly, despite complete cessation of proliferation
for over 72 hr these cells remained viable, and a substantial frac-
tion of the cells had a DNA content between 2N and 4N suggest-
ing that some cells were unable to progress through S-phase.
Furthermore, compared to cells proliferating in the presence of
AKB, the non-proliferating population showed a subtle accumu-
lation of cells with a DNA content less than 4N. An inability to
generate sufficient nucleotides to support DNA synthesis can
prevent progression through S-phase (Lunt et al., 2015). To
determine if a deficiency in nucleotide synthesis contributes to
the inability to proliferate in the absence of AKB, we quantified556 Cell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc.nucleotide pools in 143BCytB cells in the presence and absence
of AKB using liquid chromatographymass spectrometry (LCMS).
Because pyrimidine nucleotide pools are confounded by excess
uridine supplemented in the media, we focused analysis on pu-
rine nucleotides. Compared to AKB replete cells, cells cultured
without AKB had increased levels of the purine nucleotide
inosine-50-monophosphate (IMP) (Figure 4B). IMP is a precursor
of both guanine-50-monophosphate (GMP) and adenine-
50-monophosphate (AMP). However, despite an increase in
IMP, both GMP and AMP levels were decreased in the absence
of AKB (Figure 4B). To determine the functional significance of
the purine nucleotide deficiency, we supplemented 143B CytB
cells with exogenous adenine, guanine, and hypoxanthine. Using
nucleotide salvage pathways, these nucleobases are converted
to AMP, GMP, and IMP, respectively. Whereas hypoxanthine
had no effect on proliferation and guanine supplementation
was slightly toxic, adenine supplementation restored prolifera-
tion for one doubling, and alleviated the accumulation of cells
with DNA content less than 4N (Figures 4C and S3A). These
AB
DC
Figure 4. Electron Acceptor Insufficiency
Affects Purine Nucleotide Levels
(A) Analysis of DNA content by propidium iodide
staining and flow cytometry of 143B CytB cells
cultured with our without AKB supplementation.
(B) LCMS quantification of purine nucleotide levels
in 143B CytB cells cultured with or without AKB
supplementation.
(C) Cell doublings were measured over time of
143B CytB cells cultured in unsupplemented
media or media supplemented with AKB, adenine,
hypoxanthine, or guanine.
(D) Schematic illustrating the use of IMP for
GMP and AMP synthesis. Synthesis of GMP
uses NAD+, whereas synthesis of AMP requires
aspartate.
Values in (B) and (C) denote mean ± SEM, n = 3.
See also Figure S3.data suggest that loss of respiration impairs adenine nucleotide
synthesis and that adenine nucleotide deficiency partially ex-
plains the inability of cells to proliferate in the absence of electron
acceptors.
Both the AMP/IMP ratio and the GMP/IMP ratio dramatically
decrease when AKB is withdrawn from cells cultured in the pres-
ence of this exogenous electron acceptor (Figure S3B). This
decrease in the AMP/IMP and GMP/IMP ratios suggests an
inability to convert IMP to either AMP or GMP. Conversion of
IMP to GMP consumes an NAD+ by inosine 50monophosphate
dehydrogenase (IMPDH); thus, this reaction may be inhibited
by decreased NAD+ availability (Figure 4D). In contrast, conver-
sion of IMP to AMP does not directly require oxidation but
instead consumes aspartate (Figure 4D). This suggests the pos-
sibility that decreased AMP production could be downstream of
an aspartate deficiency. Consistent with this, SAICAR, a precur-
sor to IMP that also requires aspartate for its synthesis is alsoCell 162, 552–depleted when AKB is withdrawn (Fig-
ure S3C). Importantly, an underlying
aspartate deficiency could explain the
transitory nature of adenine rescue;
adenine can only restore proliferation to
those cells in a phase of cell cycle where
adenine is limiting and fails to compen-
sate for other roles that aspartate might
play in cell growth and division.
Aspartate Synthesis Is Inhibited by
Electron Acceptor Insufficiency
For most cells in culture, carbon for de
novo aspartate synthesis is supplied
by anaplerotic glutamine (DeBerardinis
et al., 2007; Hensley et al., 2013). Gluta-
mine is converted to glutamate, which
enters the TCA cycle upon conversion
to alpha-ketoglutarate (AKG) by gluta-
mate dehydrogenase (GDH) or transami-
nation (Figure 5A). While GDH uses
NAD+ as a co-substrate, the glutamatetransaminases utilize alpha-ketoacids, such as pyruvate, as
co-substrates. Regardless of which pathway produces AKG
from glutamate, conversion of a carbon-nitrogen single bond
to a carbon-oxygen double bond necessitates that an electron
pair is transferred to an electron acceptor (Figure S4A).
Aspartate can be produced from AKG via both reductive and
oxidative pathways. Reductive synthesis of aspartate by reduc-
tive carboxylation of AKG requires high levels of AKG (Fendt
et al., 2013), and electron acceptors are needed to maintain
increased AKG pools. In addition, NAD+ dependent oxidation
of AKG is required to support reductive carboxylation of AKG,
providing another mechanism by which electron acceptors are
required for reductive aspartate synthesis (Mullen et al., 2014).
Oxidative synthesis of aspartate from AKG requires three addi-
tional oxidation reactions requiring net transfer of two electron
pairs, thus imposing a further requirement for additional electron
acceptors toproduceaspartate oxidatively fromAKG (Figure 5A).563, July 30, 2015 ª2015 Elsevier Inc. 557
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Figure 5. Electron Acceptor Insufficiency
Suppresses TCA Metabolite and Aspartate
Levels
(A) Schematic detailing the TCA-cycle reaction
routes for the biosynthesis of aspartate from
glutamine.
(B) Isotopomer distribution of aspartate from 143B
CytB cells supplemented with AKB and 143B cells
cultured in the presence of U-13C Glutamine for
8 hr.
(C) GCMS quantification of TCA-cycle metabo-
lites, glutamate, and aspartate from 143B CytB
cells cultured with or without AKB.
(D) GCMS quantification of TCA metabolites,
glutamate, and aspartate from 143B cells cultured
with or without AKB in the presence or absence of
the indicated mitochondrial inhibitors. Ion counts
are relative to untreated 143B cells, which is de-
noted by the dashed gray line in each panel.
Values denote mean ± SEM, n = 3. See also
Figure S4.Given that both aspartate synthesis pathways utilize electron ac-
ceptors, we reasoned that electron acceptor deficiency in respi-
ration-inhibited cells could limit aspartate production and result
in aspartate deficiency.
We used gas chromatography mass spectrometry (GCMS) to
measure the electron acceptor dependency of glutamate, aspar-
tate, and TCA-cyclemetabolite levels in cells. In 143BCytB cells,
which metabolize glutamine by reductive carboxylation (Fig-
ure 5B and S4B) (Mullen et al., 2012), glutamate levels are only558 Cell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc.modestly lower upon AKB withdrawal,
whereas pool sizes of TCA-cycle metab-
olites are drastically decreased (Fig-
ure 5C). Aspartate was also dramatically
decreased in these cells, supporting the
hypothesis that aspartate limitation may
explain the observed AMP/IMP imbal-
ance in cells with electron acceptor insuf-
ficiency. In wild-type 143B cells, which
normally produce aspartate by oxidative
TCA-cycle metabolism (Figure 5B and
S4B), treatment with the respiration inhib-
itors rotenone, antimycin, and oligomycin
yielded similar results, with decreases in
both TCA metabolites and aspartate but
not glutamate (Figure 5D). In all cases,
treatment with AKB restored aspartate
to levels comparable to or higher than un-
treated cells. These data demonstrate
that lack of available electron acceptors
restricts aspartate biosynthesis.
Aspartate Restores Proliferation in
Cells with Electron Acceptor
Insufficiency
To determine if electron acceptor defi-
ciency inhibits proliferation because ofan effect on aspartate biosynthesis, we tested whether exoge-
nous aspartate could replace the requirement for exogenous
electron acceptors. Strikingly, in the absence of exogenous elec-
tron acceptors, supplementation with supra-physiological levels
of aspartate was capable of supporting exponential growth of
143B CytB cells (Figure 6A). Given the decrease in other TCA-
cycle intermediates observed following electron acceptor with-
drawal, we also tested whether other TCA-cycle intermediates
or their cell-permeable derivatives could restore proliferation of
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Figure 6. Aspartate is the Key Biosynthetic
Precursor Provided by Respiration
(A) Proliferation rate of 143B CytB cells determined
in the presence or absence of aspartate.
(B) The proliferation rate of 143B cells cultured with
or without aspartate in the presence of the mito-
chondrial respiration inhibitors rotenone (Rot),
phenformin (Phen), antimycin (Ant), myxothiazol
(Myxo), azide (N3), or oligomycin (Oligo).
(C) The proliferation rate of A172, H1299, HeLa,
U87, FL5.12, and MEF cells cultured with or
without aspartate in the presence of rotenone,
antimycin, or oligomycin.
(D) Schematic detailing the role of respiration and
exogenous electron acceptors in aspartate
biosynthesis. The conversion of nutrients into
aspartate requires the removal of electrons and
therefore requires access to electron acceptors,
which can be supplied by respiration (O2) or
exogenous electron acceptors such as AKB.
Maintenance of aspartate pools supports nucleo-
tide and protein biosynthesis. Values in all figure
panels denote mean ± SEM, n = 3. See also
Figure S5.
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these cells. None were able to restore proliferation to a similar
degree as aspartate (Figures S5A and S5B). Respiration-compe-
tent 143BWT cybrid cells proliferated at similar rates in the pres-
ence or absence of aspartate (Figure S5C). Importantly, aspar-
tate does not function as an exogenous electron acceptor as it
neither increases mitochondrial oxygen consumption, nor does
it alter the NAD+/NADH ratio in 143B CytB cells (Figures S5D
and S5E). These data imply that aspartate is not an electron
acceptor but rather is itself the biosynthetic demand that be-
comes limiting for proliferation in electron acceptor deficient
cells.
Measurement of purine nucleotides shows that in 143B CytB
cells aspartate addition relieves IMP accumulation and restores
AMP pools (Figure S5F). This is consistent with the hypothesis
that under electron acceptor deficiency, aspartate is limiting
for adenine nucleotide synthesis. Aspartate treatment also
restored SAICAR levels, another intermediate limited by aspar-
tate availability (Figure S5G). Interestingly, GMP levels are not
restored by aspartate treatment, consistent with the conversion
of IMP to GMP being dependent on NAD+, which is not restored
by aspartate (Figures S5E and S5F). Indeed, GMP levels were
lower in aspartate-treated cells, likely a result of decreased
IMP availability.
To determine whether aspartate is sufficient to restore prolifer-
ation in wild-type cells where respiration is inhibited, wild-type
143B cells were treated with various respiration inhibitors with
or without aspartate supplementation. Aspartate restored prolif-
eration of cells treated with all ETC inhibitors (Figure 6B). Aspar-
tate addition also rescued ETC inhibitor-induced proliferation
decreases in all other cell lines tested (Figure 6C).
Taken together, these data support a model where a major
metabolic requirement for proliferating cells fulfilled by respira-
tion is providing access to electron acceptors in the form of ox-
ygen. This access to electron acceptors is required to support de
novo aspartate biosynthesis and in the absence of mitochondrial
respiration, the demand for oxygen can be met through supple-
mentation of other electron acceptors such as pyruvate or AKB.
Alternatively, if the demand for aspartate can be met exoge-
nously, electron acceptors become dispensable for proliferation.
Surprisingly, this implies that the major function of respiration in
proliferating cells is to support aspartate synthesis (Figure 6D).
DISCUSSION
In this study we examine the role of mitochondrial respiration in
proliferative metabolism. Whereas respiration is primarily an
ATP-producing catabolic process in non-proliferating cells, in
proliferating cells respiration serves a crucial anabolic role by
providing access to electron acceptors to support aspartate
synthesis. Furthermore, mitochondrial ATP production appears
dispensable in proliferating cells with access to sufficient
glucose. Proliferating cells have different metabolic require-
ments than non-proliferating cells (Lunt and Vander Heiden,
2011); yet in both cases, the components of the metabolic
network are largely the same (Hu et al., 2013). During prolifera-
tion these same network components must take on distinct roles
to balance the contrasting anabolic and catabolic needs of the
cell. While respiration likely supports ATP production in addition560 Cell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc.to aspartate biosynthesis in many contexts, our finding that
respiration is specifically required for aspartate biosynthesis
in proliferating cells highlights a distinct anabolic role for
respiration.
All cells must perform thermodynamically unfavorable pro-
cesses. Oneway to accomplish this is to harness the free-energy
of nutrient oxidation. The source of electron donors for oxidation
varies widely across species from inorganic material for chemo-
lithotrophic bacteria to reduced carbon for most heterotrophs
including mammalian cells. In all cases, nutrient oxidation re-
quires net transfer of electrons to a terminal electron acceptor.
In mammalian cells, substrates for nutrient oxidation include
carbohydrates, lipids, and amino acids. Various metabolic path-
ways, including the TCA cycle, are employed for nutrient oxida-
tion with electrons transferred initially to electron accepting co-
factors such as NAD+ or FAD. These reactions yield NADH or
FADH2, respectively, and result in production of intermediates
with more oxidized carbon. The electrons from the reduced co-
factors are transferred to the ETC, which uses O2 as a terminal
electron acceptor to produce water and facilitate ATP produc-
tion. Importantly, ATP production through this process intimately
couples the oxidation of carbon substrates to O2 consumption.
In contexts where mammalian cells cannot utilize O2 as a ter-
minal electron acceptor, cells are unable to regenerate oxidized
cofactors via the ETC. Cells can ferment pyruvate to lactate
to regenerate NAD+; however, because the glyceraldehyde
3-phosphate dehydrogenase (GAPDH) step of glycolysis con-
sumes NAD+, use of glucose-derived pyruvate for lactate
fermentation does not net yield NAD+. Thus, in the absence of
access to exogenous electron acceptors, in order to maintain
redox balance and sustain glycolytic ATP production most
glucose carbon metabolized via glycolysis past the GAPDH
step must be excreted as lactate. While fermentation can pro-
duce sufficient ATP for proliferation, it is a redox neutral pathway.
In the absence of exogenous electron acceptors cells cannot net
synthesize molecules that are more oxidized than the nutrients
consumed. Thus, losing oxygen as an electron acceptor results
in the inability to net remove electrons from consumed carbon
substrates.
Proliferating cells must duplicate all cell components, some
of which are more oxidized than the nutrients consumed. This
suggests that net removal of electrons from carbon is an intrinsic
anabolic requirement to support production of oxidized mole-
cules, such as nucleotides, for biomass accumulation. The
need to oxidize nutrients to generate biomass may result in elec-
tron acceptor insufficiency and limit proliferation even in the
presence of oxygen. Notably, the NAD+/NADH ratio in normoxic
cancer cells is more reduced than previously assumed (Hung
et al., 2011; Zhao et al., 2015), consistent with oxidation capacity
being constrained. Because the NAD+/NADH ratio and the
pyruvate/lactate ratio are tightly coupled in cells (Williamson
et al., 1967), a low NAD+/NADH ratio is expected to drive
increased pyruvate to lactate conversion. This raises the possi-
bility that the Warburg effect is a reflection of electron acceptor
insufficiency.
Here, we find that electron acceptors are most limiting for de
novo aspartate synthesis. While cells in culture are exposed to
atmospheric oxygen, oxygen availability in animal tissues is
much lower (Bertout et al., 2008). Therefore, it may be advanta-
geous for cells to utilize less oxidative pathways when electron
acceptors become more limiting. The need for electron accep-
tors is decreased when metabolic pathways that fix CO2 are
used for de novo aspartate synthesis. For instance, pyruvate
carboxylation produces oxaloacetate that can be transaminated
to form aspartate. Alternatively, reductive AKG carboxylation
can generate isocitrate, which can be isomerized to citrate,
cleaved to form oxaloacetate, and transaminated to produce
aspartate. In both cases, fully oxidized carbon is incorporated
to produce aspartate without directly requiring net removal of
electrons. However, pyruvate and AKG are themselves oxidized
relative to the major nutrients glucose and glutamine, imposing a
need for electron acceptors to produce these carboxylation
pathway substrates. Furthermore, the ability to maintain
increased levels of pyruvate or AKG to support pyruvate carbox-
ylation or reductive isocitrate dehydrogenase metabolism is
compromised in electron acceptor deficient cells as illustrated
by the dramatic fall in AKG levels when respiration is inhibited
(Figures 5B and 5C). Therefore, regardless of the biosynthesis
pathway used, electron acceptor insufficiency will limit aspartate
synthesis.
Beyond its role as an amino acid in proteins, aspartate is
required for conversion of IMP to AMP in de novo purine synthe-
sis and provides the carbon backbone for de novo pyrimidine
synthesis. Thus, aspartate deficiency will impair protein, purine
nucleotide, and pyrimidine nucleotide synthesis. Notably, aspar-
tate is inefficiently transported into most mammalian cells
(Birsoy et al., 2015, this issue), with supra-physiological concen-
trations required to restore growth in electron acceptor deficient
cells. The concentration of aspartate in blood is around 10 mM,
among the lowest levels of all circulating amino acids (Mayers
and Vander Heiden, 2015). Additionally, aspartate aminotrans-
ferase is among the most abundant enzymes in the liver, sug-
gesting that circulating aspartate may be actively maintained
at low levels. Given the critical roles of aspartate in biosynthesis
and the challenges associated with obtaining aspartate from the
blood, access to electron acceptors for aspartate synthesis may
be a requirement for proliferation in many tumors. Consistent
with this idea, pharmacologic inhibition of ETC activity inhibits tu-
mor growth in several cancer models (Shackelford et al., 2013;
Wheaton et al., 2014; Zhang et al., 2014). Additionally, while r0
cells are unable to form xenografts, reconstituting mtDNA in
these cells restores tumorigenicity (Hayashi et al., 1992). This
requirement for mtDNA appears so stringent that, in one study,
injected r0 cells formed tumors only after acquiring mtDNA
from the host (Tan et al., 2015). While r0 cells are also expected
to be pyrimidine-limited due to loss of DHODH activity, genetic
loss of complex I, which blocks respiration but not DHODH,
also impairs tumorigenesis (Park et al., 2009).
Beyond loss of aspartate biosynthesis, we find loss of ETC
activity affects the NAD+/NADH ratio. This redox change will
also influence other pathways. For example, NAD+ is integral
to sirtuin and PARP activity, and thus, loss of ETC activity may
perturb signaling pathways (Canto´ and Auwerx, 2011). Addition-
ally, ETC activity impacts apoptosis (Newmeyer and Ferguson-
Miller, 2003; Wallace, 2012), processes that depend on the
mitochondrial membrane potential (Chen et al., 2014; Geissleret al., 2000), and reactive oxygen species (ROS) levels in cells
(Schieber and Chandel, 2014). Mutations in ETC components
resulting in partial inhibition of respiration may even be advanta-
geous for proliferation in certain contexts by increasing ROS pro-
duction (Petros et al., 2005). Nevertheless, exogenous aspartate
addition is sufficient to restore proliferation of cells that other-
wise stop proliferating or die when ETC activity is impaired.
Thus, a primary role for mitochondrial respiration in cell prolifer-
ation must be to provide access to electron acceptors in support
of aspartate synthesis.
EXPERIMENTAL PROCEDURES
Cell Culture
143B, A172, H1299, HeLa, U87, 143B cybrid cell lines (WT Cybrid and CytB),
FL5.12, and immortalized MEF cells were cultured in Dulbecco’s Modified
Eagle’s Medium (DMEM) (GIBCO) supplemented with 10% fetal bovine serum
and penicillin-streptomycin. FL5.12 cells were supplemented with 5 mg/ml re-
combinant mouse IL-3 (R&D Systems), and 143B cybrid cells were supple-
mented 0.1 mg/ml uridine. All cells were incubated at 37C with 5% CO2.
Proliferation Rates
Cell were plated onto replicate 6-well dishes (Corning), with initial seeding den-
sity of 20,000 cells per well for 143B, A172, H1299, HeLa, 143B WT Cybrid,
FL5.12, and MEFs and 30,000 cells for 143B CytB and U87 cells. After over-
night incubation for cells to adhere, 6 wells were counted to determine initial
count at time of treatment. Cells were washed twice in phosphate buffered sa-
line (PBS) and 4 ml of treatment media was added. Final cell counts were
measured 4 days after treatment, and proliferation rate was calculated. See
Supplemental Experimental Procedures for detailed protocol. Concentrations
of all metabolites and compounds added to culture media for each cell line are
included as a table in Supplemental Experimental Procedures (Table S1).
Mitochondrial Oxygen Consumption
Oxygen consumption rates were determined using a Seahorse Bioscience
Extracellular Flux Analyzer (XF24). See Supplemental Experimental Proce-
dures for detailed protocol.
Purine Nucleotide Metabolite Extraction and LCMS Analysis
Cells were treated as indicated for 15 hr and polar metabolites were extracted.
A Dionex UltiMate 3000 ultra-high performance liquid chromatography system
connected to a Q Exactive benchtop Orbitrap mass spectrometer, equipped
with an Ion Max source and a HESI II probe (Thermo Fisher Scientific), was
used to quantify metabolites. See Supplemental Experimental Procedures
for detailed extraction and LCMS conditions.
Amino Acid and TCA-Cycle Metabolite Extraction and GCMS
Analysis
Cells were seeded at 400,000 cells/well in 6-well dishes overnight. The
following day cells were washed twice in PBS and media was changed to
media containing the indicated treatments. After 8 hr, polar metabolites
were extracted using 80% methanol in water with 1 mg norvaline standard
added per sample. Soluble content was dried under nitrogen gas. Polar sam-
ples were derivatized and measured as previously detailed (Lewis et al., 2014).
Relative metabolite abundances were determined by integrating ion peak area
(Metran) and normalized to norvaline internal extraction standard.
Cell-Cycle Distribution Measurements
Cells were incubated with or without AKB or 100 mM adenine as indicated for
78 hr before being washedwith PBS, trypsinized, pelleted, and resuspended in
500 ml PBS. Cells were fixed by adding 4.5 ml 70% ethanol and incubated at
4C overnight. Cells were then pelleted and resuspended in 1 ml PBS +
0.1% (v/v) Triton X-100. RNase A and propidium iodide (PI) were added to
0.2 mg/ml and 20 mg/ml, respectively. Samples were incubated at 37C forCell 162, 552–563, July 30, 2015 ª2015 Elsevier Inc. 561
15 min and filtered into a flow cytometry tube. DNA content was measured by
flow cytometry (BD FACS Canto II) and analyzed (FACS Diva Software).
Measurement of NAD+/NADH
Cells were plated in the same manner as proliferation assays and treated as
indicated prior to preparation of cell extracts 6 hr after treatment. NAD+/
NADH was measured using a modified version of the manufacturer instruc-
tions supplied with the NAD/NADH Glo Assay (Promega). See Supplemental
Experimental Procedures for a detailed protocol.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.cell.2015.07.017.
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